Who
Matthew Wein
Officer
Company insider
Files Form 4 as: Officer, Metagenomi Therapeutics.
In numbers
- Trades disclosed
- 21
- Buys
- 0
- Sells
- 7
- Bought
- $0
- Sold
- $6,622
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Apr 2024
- Last trade
- 8 Sep 2026
- Last filed
- 10 Sep 2026
Companies traded
Activity over time
1 Mar 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Sep 2026filed 10 Sep 2026 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Sold | $415358 at $1.16 | filing |
| 8 Sep 2026filed 10 Sep 2026 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Sold | $415358 at $1.16 | filing |
| 5 Jun 2026filed 10 Jun 2026 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Sold | $725558 at $1.30 | filing |
| 5 Jun 2026filed 10 Jun 2026 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Sold | $725558 at $1.30 | filing |
| 1 Apr 2026filed 3 Apr 2026 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Code A | —11,000 at $0.00 | filing |
| 1 Apr 2026filed 3 Apr 2026 | MGX Metagenomi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —68,000 at $0.00 | filing |
| 1 Apr 2026filed 3 Apr 2026 | MGX Metagenomi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —68,000 at $0.00 | filing |
| 1 Apr 2026filed 3 Apr 2026 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Code A | —11,000 at $0.00 | filing |
| 5 Mar 2026filed 9 Mar 2026 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Sold | $771482 at $1.60 | filing |
| 5 Mar 2026filed 9 Mar 2026 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Sold | $771482 at $1.60 | filing |
| 5 Dec 2025filed 8 Dec 2025 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Sold | $352199 at $1.77 | filing |
| 1 Dec 2025filed 1 Dec 2025 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Code A | $154K96,000 at $1.60 | filing |
| 5 Sep 2025filed 1 Dec 2025 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Sold | $360199 at $1.81 | filing |
| 6 Jun 2025filed 9 Jun 2025 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Sold | $348199 at $1.75 | filing |
| 1 Apr 2025filed 3 Apr 2025 | MGX Metagenomi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,875 at $0.00 | filing |
| 1 Apr 2025filed 3 Apr 2025 | MGX Metagenomi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,725 at $0.00 | filing |
| 1 Apr 2025filed 3 Apr 2025 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Code A | —3,650 at $0.00 | filing |
| 1 Apr 2025filed 3 Apr 2025 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Code A | —3,775 at $0.00 | filing |
| 5 Mar 2025filed 7 Mar 2025 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Sold | $1,739930 at $1.87 | filing |
| 1 Apr 2024filed 3 Apr 2024 | MGX Metagenomi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —43,717 at $0.00 | filing |
News
Eddie Murphy to star in drama series 'The Chairman' from 'Mad Men' creator Matthew Weineraninews.in · 2 Oct 2026
1 headline in the last 90 days name Matthew Wein; 0 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.